文献速递妇科

循环T细胞受体多样性作为高级别浆液性卵巢癌PARP抑制剂维持治疗预测生物标志物

Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-11-25

研究纳入27例高级别浆液性卵巢癌患者,其中22例接受PARP抑制剂维持治疗、5例未治疗作为对照,在基线及暴露后1个月、3个月采集外周血进行T细胞受体测序。接受PARP抑制剂者T细胞受体库较未治疗者更稳定;治疗3个月后T细胞受体多样性上升趋势与更长无进展生存期(21.7 vs 7.4个月,风险比=0.19,p<0.001)及更好缓解(91.7% vs 25.0%,p=0.004)相关。作者提出循环T细胞受体多样性可能是PARP抑制剂维持治疗的潜在预测生物标志物。

要点

  • 22例接受PARP抑制剂维持治疗者T细胞受体库较5例未治疗对照更稳定。
  • 治疗3个月后T细胞受体多样性上升趋势与更长无进展生存期相关(21.7 vs 7.4个月,风险比=0.19,p<0.001)。
  • 该多样性上升趋势亦与更好缓解相关(91.7% vs 25.0%,p=0.004)。

核心结论

  • 作者提出循环T细胞受体多样性可能是高级别浆液性卵巢癌PARP抑制剂维持治疗的潜在预测生物标志物。

研究设计与样本

  • 研究分析27例高级别浆液性卵巢癌患者,其中22例接受PARP抑制剂维持治疗,5例未治疗患者作为对照。
  • 在基线以及暴露于PARP抑制剂后1个月和3个月采集外周血样本进行T细胞受体测序。
  • 比较接受与未接受PARP抑制剂患者的T细胞受体库,并将治疗组T细胞受体多样性与PARP抑制剂疗效进行关联分析。

主要发现

  • 接受PARP抑制剂患者的T细胞受体库较未治疗病例更稳定。
  • PARP抑制剂治疗3个月后T细胞受体多样性上升趋势与更长无进展生存期相关(21.7 vs 7.4个月,风险比=0.19,p<0.001)。
  • 该多样性上升趋势与更好缓解相关(91.7% vs 25.0%,p=0.004)。
  • 对PARP抑制剂有效性具有预测价值的主要特征是高频率T细胞克隆的显著减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: T-cell receptor (TCR) repertoire diversity is getting increasing attention as a predictive biomarker in cancer patients. However, the characteristics of the TCR together with its predictive significance for high grade serous ovarian cancer (HGSOC) patients receiving poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy remain unknown. METHODS: Twenty-seven patients with HGSOC were analyzed including 22 patients receiving PARPi maintenance therapy and 5 untreated patients as control. Peripheral blood samples were collected for TCR sequencing at baseline as well as one month and three months after the exposure to PARPi. To determine whether TCR diversity was related to PARPi efficacy, we compared the TCR repertoire between patients who had received PARPi and those who had not. RESULTS: For patients receiving PARPi treatment or not, we evaluated changes in clone abundance during PARPi maintenance and the similarity of the TCR repertoire before and after the treatment. The results revealed that patients receiving PARPi had TCR repertoires that were more stable than those of untreated cases. We next correlated TCR diversity with the efficacy of PARPi in the treatment group. The rising trend of TCR diversity after three months with PARPi treatment was associated with a longer PFS (21.7 vs 7.4 months, hazard ratio = 0.19, p < 0.001) and a better response to PARPi (91.7% vs 25.0%, p = 0.004). Furthermore, we discovered that the primary characteristic with predictive value for the effectiveness of PARPi is the considerable reduction of the high-frequency T cell clones. CONCLUSION: We suggested that the circulating TCR diversity could be a potential predictive biomarker for PARPi maintenance therapy in HGSOC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Shu T, Zhou Z, Bai J, et al. Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. Gynecol Oncol. 2022. PMID: 36442424. doi:10.1016/j.ygyno.2022.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。